

| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 2,146.29 | 1,816.70 | 1,381.54 | 1,317.34 | 1,285.32 |
| Total Expenses | 1,991.70 | 1,844.05 | 1,519.33 | 1,294.31 | 1,233.50 |
| Profit Before Tax | 154.59 | -84.96 | -176.36 | 21.97 | 51.48 |
| Profit After Tax | 137.52 | -93.76 | -202.23 | 33.06 | 34.32 |
| Operating Profit After Depreciation | 175.62 | -4.69 | -120.48 | 29.14 | 56.94 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,299.57 | 1,252.40 | 1,256.66 | 990.03 | 880.42 |
| Total Non Current Assets | 1,539.93 | 1,531.63 | 1,604.58 | 1,670.38 | 1,748.40 |
| Total Current Assets | 2,029.47 | 1,743.32 | 1,588.47 | 1,648.39 | 1,377.32 |
| Total Assets | 3,569.40 | 3,274.95 | 3,193.05 | 3,318.77 | 3,125.71 |
| Total Shareholder's Fund | 2,450.59 | 2,438.30 | 2,435.30 | 2,618.41 | 2,556.83 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | -7.02 | 14 | -85.09 | -259.61 | 32.98 |
| Net Cash Used In Investing Activities | -241.91 | 63.31 | 240.95 | 100.12 | -65.97 |
| Net Cash Used In Financing Activities | 183.76 | -106.31 | -81.30 | 191.23 | -121.07 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,776.53 | 1,472.55 | 1,114.28 | 984.99 | 1,171.34 |
| Total Expenses | 1,597.85 | 1,507.12 | 1,280.70 | 1,071.74 | 1,105.70 |
| Profit Before Tax | 182.68 | -92.18 | -279.09 | -86.75 | 65.65 |
| Profit After Tax | 162.96 | -92.18 | -299.70 | -55.43 | 54.08 |
| Operating Profit After Depreciation | 186.30 | -24.15 | -157.05 | -84.67 | 66.95 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,274.69 | 1,164.94 | 1,235.94 | 963.12 | 846.23 |
| Total Non Current Assets | 1,542.87 | 1,457.57 | 1,593.38 | 1,748.12 | 1,813.69 |
| Total Current Assets | 1,566.34 | 1,383.94 | 1,292.76 | 1,373.96 | 1,305.37 |
| Total Assets | 3,109.21 | 2,841.51 | 2,886.14 | 3,122.08 | 3,119.06 |
| Total Shareholder's Fund | 2,459.75 | 2,294.63 | 2,384.27 | 2,672.04 | 2,697.33 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 72.29 | -41.57 | -117.33 | -158.31 | -32.61 |
| Net Cash Used In Investing Activities | -132.75 | 59.61 | 240.63 | 104.03 | -72.79 |
| Net Cash Used In Financing Activities | -4.61 | -48.06 | -61.76 | 95.80 | -45.07 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 575.12 | 521.17 | 578.96 | 526.60 | 587.18 |
| Total Expenses | 527.44 | 476.39 | 512.78 | 504.11 | 503.48 |
| Profit Before Tax | 18.79 | 293.43 | -10.82 | -9.02 | 57.80 |
| Profit After Tax | 10.91 | 264.29 | -11.89 | -10.47 | 52.97 |
| Operating Profit after Depreciation | 71.15 | 56.58 | 87.15 | 29.31 | 92.95 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 356.24 | 314.90 | 356.90 | 384.25 | 461.24 |
| Total Expenses | 343.75 | 313.51 | 349.20 | 358.51 | 386.26 |
| Profit Before Tax | -10.71 | 259.82 | -37.83 | -1.87 | 56.03 |
| Profit After Tax | -15.39 | 216.11 | -39.93 | -1.85 | 51.22 |
| Operating Profit after Depreciation | 34.71 | 16.42 | 29.10 | 29.99 | 81.03 |
₹4.0/Share
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
| Fund Name | AUM |
|---|---|
| DSP Healthcare Fund | 0.90% |
| HDFC Small Cap Fund | 0.49% |
| Bandhan BSE Healthcare Index Fund | 0.05% |
| Motilal Oswal BSE 1000 Index Fund | 0% |
On 11 August 2026
11 Jun 2026, 09:44 am
On 22 May 2026
07 May 2026, 11:20 am
Unichem Laboratories said the United States Food and Drug Administration (USFDA) inspected its Kolhapur API facility from 27 January to 2 February 2026.
02 Feb 2026, 05:34 pm
On 5 February 2026
09 Jan 2026, 05:17 pm
On 11 November 2025
31 Oct 2025, 01:56 pm

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.